Eisai CoESALF 69 Receivables Turnover is 0.86 as of Mar. 2026. GuruFocus rates ESALF with a GF Score™ of 69/100 and a GF Value™ of $33.57 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 943 Drug Manufacturers companies, Eisai Co ranks worse than 71.69% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Eisai Co's Revenue for the
three
months ended in Mar. 2026 was $1,295 Mil. Eisai Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1,514 Mil.
Hence, Eisai Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.86.
Eisai Co (OTCPK:ESALF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Eisai Co Receivables Turnover Related Terms
Eisai Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Eisai Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESALF vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eisai Co Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Eisai Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eisai Co (ESALF) has a Receivables Turnover of 0.86 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Eisai Co and its competitors. According to the industry distribution chart, Eisai Co ranks #676 out of 943 companies in the Drug Manufacturers industry, placing it in the top 71.7%.
Is Eisai Co's Receivables Turnover too high?
Eisai Co's current Receivables Turnover is 0.86. The Drug Manufacturers industry median Receivables Turnover is 5.07. Eisai Co's value of 0.86 is 83% below this industry median. Based on the distribution chart, Eisai Co ranks #676 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eisai Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eisai Co ranks #676 out of 943 companies for Receivables Turnover. This places Eisai Co in the lower half of its industry. The industry median Receivables Turnover is 5.07. Eisai Co's value of 0.86 is 83% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eisai Co's current Receivables Turnover of 0.86 is 83% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Eisai Co and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eisai Co's current Receivables Turnover is 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Modestly Undervalued. The stock's GF Value™ is $33.57, compared to a current price of $25.00 — trading 25.5% below its estimated fair value. The current Receivables Turnover is 0.86 and 83% below the Drug Manufacturers industry median of 5.07. Eisai Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Eisai Co (ESALF), the current Receivables Turnover is 0.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eisai Co (ESALF) Overvalued in 2026?
Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued.
The current stock price of $25.00 is trading 25.5% below its estimated GF Value™ of $33.57.
GuruFocus considers Eisai Co to be Modestly Undervalued.
Key valuation signals for ESALF:
Receivables Turnover: 0.86
GF Value™: $33.57 vs. price of $25.00 (25.5% below fair value)
Industry Position: 83% below the Drug Manufacturers median (#676 of 943)
No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for ESALF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESALF has been successfully added to your 
